274-79-3

Usage

Uses

Used in Pharmaceutical Research:
Imidazo[1,2-a]pyrazine is used as a key intermediate in the synthesis of various pharmaceutical compounds due to its unique ring system and reactivity. It serves as a foundation for the development of new drug candidates with potential therapeutic applications.
Used in Antiviral Applications:
Imidazo[1,2-a]pyrazine and its derivatives are used as antiviral agents for their potential to inhibit viral replication and reduce the severity of viral infections.
Used in Antibacterial Applications:
Imidazo[1,2-a]pyrazine is also utilized as an antibacterial agent, where its derivatives have been studied for their ability to combat bacterial infections by disrupting essential cellular processes in bacteria.
Used in Anticancer Applications:
Imidazo[1,2-a]pyrazine is used as an anticancer agent, with its derivatives being investigated for their potential to inhibit the growth and proliferation of cancer cells, making it a promising candidate for cancer treatment.
Used in Organic Synthesis:
In the field of organic synthesis, imidazo[1,2-a]pyrazine is used as a versatile building block for the creation of a wide range of bioactive compounds, contributing to the advancement of chemical libraries and the discovery of novel therapeutic agents.

InChI:InChI=1/C6H5N3/c1-3-9-4-2-8-6(9)5-7-1/h1-5H

Upstream product

• 5049-61-6 2-Aminopyrazine 
• 107-20-0 2-chloroethanal 
• 2032-35-1 Bromoacetaldehyde diethyl acetal 
• 7252-83-7 1-bromo-2,2-dimethoxyethane 
• 97-97-2 chloroacetaldehyde dimethyl acetal 

Downstream Products

• 63744-21-8 3,5-dibromoimidazo<1,2-a>pyrazine 
• 87597-26-0 5-bromoimidazo<1,2-a>pyrazine 
• 57948-41-1 3-bromoimidazo<1,2-a>pyrazine 
• 106012-58-2 3-formylimidazo<1,2-a>pyrazine 
• 106012-57-1 3-hydroxymethylimidazo<1,2-a>pyrazine 
• 936361-36-3 3,8-dibromo-imidazo[1,2-a]pyrazine 
• 1244949-15-2 3-phenylimidazo[1,2-a]pyrazine 
• 155653-55-7 8-phenylimidazo<1,2-a>pyrazine 
• 1606131-66-1 3-(4-(ethylthio)phenyl)-5-(pyridin-3-yl)imidazo[1,2-a]pyrazine 
• 1606131-67-2 3-(4-(ethylthio)phenyl)-5-(2-methoxypyridin-4-yl)imidazo[1,2-a]pyrazine 
• 1606131-68-3 4-(3-(4-(ethylthio)phenyl)imidazo[1,2-a]pyrazin-5-yl)isoquinoline 
• 1606131-69-4 3-(3-(4-ethylphenyl)imidazo[1,2-a]pyrazin-5-yl)quinoline 
• 1606131-43-4 3-(4-(trifluoromethyl)phenyl)imidazo[1,2-a]pyrazine 
• 1606131-44-5 3-(4-(ethylthio)phenyl)imidazo[1,2-a]pyrazine 

Relevant academic research and scientific papers

From Synthetic Simplified Marine Metabolite Analogues to New Selective Allosteric Inhibitor of Aurora B Kinase

Significant inhibition of Aurora B was achieved by the synthesis of simplified fragments of benzosceptrins and oroidin belonging to the marine pyrrole-2-aminoimidazoles metabolites isolated from sponges. Evaluation of kinase inhibition enabled the discovery of a synthetically accessible rigid acetylenic structural analogue EL-228 (1), whose structure could be optimized into the potent CJ2-150 (37). Here we present the synthesis of new inhibitors of Aurora B kinase, which is an important target for cancer therapy through mitosis regulation. The biologically oriented synthesis yielded several nanomolar inhibitors. The optimized compound CJ2-150 (37) showed a non-ATP competitive allosteric mode of action in a mixed-type inhibition for Aurora B kinase. Molecular docking identified a probable binding mode in the allosteric site "F"and highlighted the key interactions with the protein. We describe the improvement of the inhibitory potency and specificity of the novel scaffold as well as the characterization of the mechanism of action.

Deuterated acetylene derivatives, its pharmaceutical composition and application

The invention discloses a deuterated acetylenic derivative, a pharmaceutical composition and application thereof. The deuterated acetylenic derivative comprises one or more of the deuterated acetylenic derivative (I) with curative effective dose, pharmace

A 5, 6, 7, 8-tetrahydro-imidazol [1,2-A] pyrazine synthetic method

The invention discloses a method for synthesizing 5,6,7,8-tetrahydroimidazole-[1,2-A]-pyrazine. The method comprises the following steps: reacting tetramethypyrazine with chloroacetaldehyde dimethyl to generate indol-[1,2-A]-pyrazine; performing hydrogenation reduction reaction on indol-[1,2-A]-pyrazine in the presence of a palladium-carbon catalyst to generate 5,6,7,8-tetrahydroimidazole-[1,2-A]-pyrazine. The method has the beneficial effects that the raw materials are easily available, the reaction conditions are mild, low-cost chloroacetaldehyde dimethyl and palladium-carbon catalyst are adopted, and the large-scale production is facilitated.

BETA-AMINO HETEROCYCLIC DIPEPTIDYL PEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES

The present invention is directed to compounds which are inhibitors of the dipeptidyl peptidase-IV enzyme (“DP-IV inhibitors”) and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved.

Aurora Kinase Modulators and Method of Use

The present invention relates to chemical compounds having a general formula I wherein A1-8, D′, L1, L2, R1, R6-8 and n are defined herein, and synthetic intermediates, which are capable of modulating various protein kinase receptor enzymes and, thereby, influencing various disease states and conditions related to the activities of such kinases. For example, the compounds are capable of modulating Aurora kinase thereby influencing the process of cell cycle and cell proliferation to treat cancer and cancer-related diseases. The invention also includes pharmaceutical compositions, including the compounds, and methods of treating disease states related to the activity of Aurora kinase.

PHTHALAZINONE KETONE DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL USE THEREOF

A phthalazinone ketone derivative as represented by formula (I), a preparation method thereof, a pharmaceutical composition containing the derivative, a use thereof as a poly (ADP-ribose) polymerase (PARP) inhibitor, and a cancer treatment method thereof.

PHTHALAZINONE KETONE DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL USE THEREOF

A phthalazinone ketone derivative as represented by formula (I), a preparation method thereof, a pharmaceutical composition containing the derivative, a use thereof as a poly (ADP-ribose) polymerase (PARP) inhibitor, and a cancer treatment method thereof are described.

METHODS AND COMPOSITIONS FOR RAF KINASE MEDIATED DISEASES

The invention discloses methods and compositions for treating or preventing RAF kinase mediated diseases or conditions by administering a compound of Formula 1: or a pharmaceutically acceptable salt, solvate or hydrate thereof, wherein the variables are defined as herein.

5,6,7,8-TETRAHYDROIMIDAZO[1,2-A]PYRAZINE DERIVATIVES AS P2X7 MODULATORS

The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof: wherein A is hydrogen, C1-4alkyl, C3-6cycloalkyl, C1-3alkoxy, C1-3alkoxy C1-4alkyl, C1-2/s

Substituted Sulfonamide Compounds

Substituted sulfonamide compounds corresponding to the formula I wherein m, n, p, Q, R1, R2, R3, R4, X, Y and Z have the respective meanings defined herein, pharmaceutical compositions containing such compounds, a process for their preparation, and the use of such compounds for the treatment and/or inhibition of pain and other conditions mediated by bradykinin receptor 1 (B1R) and/or bradykinin receptor 2 (B2R).